NO CHANGES IN BLOOD PRESSURE IN DIALYSIS PATIENTS AFTER 12 MONTHS OF TREATMENT WITH IV/SC CERA (CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR)

被引：0
|
作者：
Dougherty, Frank C.
Beyer, Ulrich
机构：
来源：
NEPHROLOGY | 2005年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A313 / A314
页数：2
相关论文
共 50 条
  • [31] BLOOD PRESSURE IN PRE-DIALYSIS PATIENTS WITH AND WITHOUT ERYTHROPOIETIN TREATMENT
    Suttorp, Marit M.
    Hoekstra, Tiny
    Dekker, Friedo W.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 87 - 88
  • [32] CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR (CERA) TREATMENT PREVENTS GLOMERULOSCLEROSIS AND SUPPRESSES ACTIVATION OF ALTERNATIVELY ACTIVATED MACROPHAGES IN A RAT MODEL OF ACUTE GLOMERULONEPHRITIS
    Hirata, Michinori
    Tashiro, Yoshihito
    Endo, Koichi
    Aizawa, Ken
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 358 - 358
  • [33] Intravenous CERA (continuous erythropoictin receptor activator) administered up to once monthly maintains Hb levels in patients with diabetes on dialysis
    Mann, J. F.
    Combe, C.
    Donnelly, S. M.
    Dougherty, F. C.
    [J]. DIABETOLOGIA, 2006, 49 : 650 - 651
  • [34] Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study
    Hidehiro Tabata
    Hiroyuki Kanno
    Ayako Murayama
    Tadashi Ishii
    Ryosuke Harada
    Yukio Udagawa
    [J]. Renal Replacement Therapy, 5
  • [35] HEMOGLOBIN OUTCOMES DURING TWO YEARS' TREATMENT WITH CONTINUOUS ERYTHROPOIETIN ACTIVATOR (CERA) UNDER ROUTINE CONDITIONS IN PATIENTS WITH DIALYSIS-DEPENDENT OR NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (CKD)
    Galle, Jan
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [36] Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study
    Tabata, Hidehiro
    Kanno, Hiroyuki
    Murayama, Ayako
    Ishii, Tadashi
    Harada, Ryosuke
    Udagawa, Yukio
    [J]. RENAL REPLACEMENT THERAPY, 2019, 5 (01)
  • [37] CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR (CERA) ONCE MONTHLY MAINTAINS STABLE HEMOGLOBIN VALUES IN HIGH-RISK PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS: AN ANALYSIS OF 10 INTERNATIONAL TRIALS
    Fliser, Danilo
    Shilo, Valery
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 133 - 133
  • [38] Subcutaneous Continuous Erythropoietin Receptor Activator Conversion Provides Practical Advantages and Potential Convenience for Peritoneal Dialysis Patients
    Chen, Chun-Yu
    Hsu, Heng-Jung
    Lin, Yu-Ying
    Wu, Mai-Szu
    [J]. PERITONEAL DIALYSIS INTERNATIONAL, 2011, 31 (05): : 592 - 595
  • [39] Efficacy of continuous erythropoietin receptor activator for end-stage renal disease patients with renal anemia before and after peritoneal dialysis initiation
    Fujimoto, Daisuke
    Adachi, Masataka
    Miyasato, Yoshikazu
    Hata, Yusuke
    Inoue, Hideki
    Oda, Akira
    Kakizoe, Yutaka
    Nakagawa, Terumasa
    Shimasaki, Akiko
    Nakamura, Keishi
    Nagayoshi, Yu
    Mukoyama, Masashi
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (02) : 191 - 199
  • [40] Efficacy of continuous erythropoietin receptor activator for end-stage renal disease patients with renal anemia before and after peritoneal dialysis initiation
    Daisuke Fujimoto
    Masataka Adachi
    Yoshikazu Miyasato
    Yusuke Hata
    Hideki Inoue
    Akira Oda
    Yutaka Kakizoe
    Terumasa Nakagawa
    Akiko Shimasaki
    Keishi Nakamura
    Yu Nagayoshi
    Masashi Mukoyama
    [J]. Clinical and Experimental Nephrology, 2021, 25 : 191 - 199
12345